Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 3/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRE | P78334 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.40 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.40 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.40 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.40 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.38 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL853339 | 0.89 | SLC6A1 (0.44) | GABRA5GABRB2GABRA1GABRA4SLC6A1 | |
| Hydrochloric Acid SCHEMBL6313494 | 0.87 | SLC6A1 (0.43) | GABRA5GABRB2GABRA1GABRA4SLC6A1 | |
| SCHEMBL1513993 | 0.85 | — | — | |
| SCHEMBL7812304 | 0.84 | SLC6A4 (0.36) | GABRA5GABRB2GABRA1GABRA4GABRP | |
| SCHEMBL4323487 | 0.83 | ALDH1A1 (0.47) | ALDH1A1 | |
| SCHEMBL21164893 | 0.83 | ALDH1A1 (0.47) | ALDH1A1 | |
| SCHEMBL3436142 | 0.82 | DDB1 (0.45) | GABRA5GABRB2GABRA1GABRA4GABRP | |
| SCHEMBL8851488 | 0.82 | SLC6A4 (0.35) | GABRA5GABRB2GABRA1GABRA4GABRP | |
| SCHEMBL2796886 | 0.81 | ALDH1A1 (0.50) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL17275903 | 0.79 | ITGB3 (0.42) | GABRA5GABRB2GABRA1GABRA4GABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117858874-A | HPK1 degrading agents, compositions comprising the same, and methods of use thereof | 百放开曼有限公司 | 2024-04-09 | — | — | CN | disclosed |
| EP-2699546-B1 | GAS CAPTURE PROCESS | COMMONWEALTH SCIENT & INDUSTRIAL RESEARCH ORGANISATION (AU) | 2019-06-26 | — | — | EP | disclosed |
| US-9409122-B2 | Gas capture process | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2016-08-09 | — | — | US | disclosed |
| US-9409122-B2 | Gas capture process | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2016-08-09 | — | — | US | disclosed |
| US-20140127103-A1 | GAS CAPTURE PROCESS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2014-05-08 | — | — | US | disclosed |
| US-20140127103-A1 | GAS CAPTURE PROCESS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2014-05-08 | — | — | US | disclosed |
| US-7776897-B2 | such as 3-[1-(5-chloro-2-thienyl)cyclopenty]-5,6,7,8,9,10-hexahydro [1,2,4]triazolo[4,3-a]azocine, having a strong 11 beta -hydroxysteroid dehydrogenase type 1inhibitory activity and exhibiting an excellent blood-glucose level-lowering action, used for the therapy of diabetes and insulin resistance | ASTELLAS PHARMA INC. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-7776897-B2 | such as 3-[1-(5-chloro-2-thienyl)cyclopenty]-5,6,7,8,9,10-hexahydro [1,2,4]triazolo[4,3-a]azocine, having a strong 11 beta -hydroxysteroid dehydrogenase type 1inhibitory activity and exhibiting an excellent blood-glucose level-lowering action, used for the therapy of diabetes and insulin resistance | ASTELLAS PHARMA INC. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20070259854-A1 | Triazole Derivative or Salt Thereof | ASTELLAS PHARMA INC. (JP) | 2007-11-08 | — | — | US | disclosed |
| US-20070259854-A1 | Triazole Derivative or Salt Thereof | ASTELLAS PHARMA INC. (JP) | 2007-11-08 | — | — | US | disclosed |
| EP-1790641-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259854-A1 | Triazole Derivative or Salt Thereof | HSD11B1, HSD11B2, HSD3B1 | GABRA5 2030/4885GABRB2 1850/4885GABRA1 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.